{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} New Study Tracks Accelerating Use of Biomarkers in Cancer Clinical Trials
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide information on the incorporation of biomarkers in cancer clinical trials to develop biomarker-based therapies.Learning Objectives
After completing this continuing education activity you will be able to:
- Assess the implications of the current shift in drug development toward biomarker-based therapies.
- Analyze the challenges of personalized cancer therapies that are based on biomarkers.
Disclosures
The author(s), faculty, staff, and planners, including spouses/partners (if any), in any position to control the content of this activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies relevant to this educational activity.
Price:
$12.95
Credits:
- ANCC 1.0 CH
- DC - BON 1.0 CH
- FL - BON 1.0 CH
- GA - BON 1.0 CH
Lippincott Professional Development is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, and Georgia Board of Nursing, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: OT1219
Published: December 2019
Expires: 12/6/2024
Sources:
Oncology Times
Required Passing Score: 8/10 (80%)
Specialties:
Oncology